Acorda Therapeutics is a publicly traded (NASDAQ: ACOR) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders.
We started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders.
We have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. We achieve our goals by:
• investing in research and development
• collaborating closely with the patient, medical and scientific communities
• retaining employees with compassion and commitment
Acorda has been voted one of the best companies to work for in New York for the past five years in a row, as a result of our dynamic environment, strong corporate culture, significant emphasis on research and development, and a robust product pipeline. We are positioned to be an industry leader, poised for exceptional growth.
Closing share price
|FY, 2013||FY, 2014||FY, 2015||FY, 2016|
|$336.4 m||$401.5 m||$492.7 m||$519.6 m|
Revenue growth, %
|$270.4 m||$321.5 m||$400.4 m|
Operating expense total
|$306.1 m||$365.1 m||$458.7 m|
|$30.4 m||$36.4 m||$34 m|
|$16.4 m||$17.7 m||$11.1 m||($35.6 m)|
Operating cash flow
|$6.2 m||$134.1 m||($29 m)|